Palladium Pd-103
Term · Oncology and biomedicine · MLC-T-ONC-015779
A radioisotope of the metal palladium used in brachytherapy implants or 'seed'. With a half-life of 17 days, palladium 103 administered with brachytherapy allows continuous, tumor-site specific low-energy irradiation to the tumor cell population while sparing normal adjacent tissues from radiotoxicity.
| Identifier | MLC-T-ONC-015779 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | Pd 103 |
| Synonyms | palladium 103; palladium Pd 103; palladium-103 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015779",
"term": "Palladium Pd-103",
"field": "Oncology and biomedicine",
"definition": "A radioisotope of the metal palladium used in brachytherapy implants or 'seed'. With a half-life of 17 days, palladium 103 administered with brachytherapy allows continuous, tumor-site specific low-energy irradiation to the tumor cell population while sparing normal adjacent tissues from radiotoxicity.",
"abbreviation": "Pd 103",
"synonyms": [
"palladium 103",
"palladium Pd 103",
"palladium-103"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/palladium-pd-103/"
}
Record 12,529 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.